

Title (en)

COMBINED PHARMACEUTICAL COMPOSITION OF C-MET KINASE INHIBITOR AND ANTI-PD-L1 ANTIBODY

Title (de)

KOMBINIERTE PHARMAZEUTISCHE ZUSAMMENSETZUNG AUS C-MET-KINASEHEMMER UND ANTI-PD-L1-ANTIKÖRPER

Title (fr)

COMPOSITION PHARMACEUTIQUE COMBINÉE D'INHIBITEUR DE KINASE C-MET ET D'ANTICORPS ANTI-PD-L1

Publication

**EP 4159238 A4 20240807 (EN)**

Application

**EP 21817364 A 20210601**

Priority

- CN 202010489252 A 20200602
- CN 202010489236 A 20200602
- CN 2021097776 W 20210601

Abstract (en)

[origin: EP4159238A1] Provided are a combined pharmaceutical composition of an anti-PD-L1 antibody and a c-Met kinase inhibitor, specifically, a combined pharmaceutical composition of an anti-PD-L1 antibody and N-(4-((7-((1-(cyclopentylamino)cyclopropyl)methoxy)-6-methoxyquinolin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and the use of the combined pharmaceutical composition in the treatment of cancers, in particular, gastric cancer or liver cancer.

IPC 8 full level

**C07K 16/28** (2006.01); **A61K 31/00** (2006.01); **A61K 39/395** (2006.01); **A61P 35/00** (2006.01); **C07D 215/22** (2006.01)

CPC (source: EP US)

**A61K 31/47** (2013.01 - EP US); **A61K 39/395** (2013.01 - EP); **A61K 39/3955** (2013.01 - US); **A61P 35/00** (2018.01 - EP US); **C07D 215/22** (2013.01 - EP); **C07K 16/2827** (2013.01 - EP); **A61K 2039/505** (2013.01 - EP); **A61K 2039/545** (2013.01 - US); **C07K 2317/24** (2013.01 - EP); **C07K 2317/76** (2013.01 - EP)

C-Set (source: EP)

1. **A61K 39/395 + A61K 2300/00**
2. **A61K 31/47 + A61K 2300/00**

Citation (search report)

- [Y] US 2019224200 A1 20190725 - MARTIN ERIC SANTOS [US], et al
- [Y] WO 2016061142 A1 20160421 - NOVARTIS AG [CH], et al
- [Y] WO 2012034055 A2 20120315 - ADVENCHEN LAB LLC [US]
- [Y] WO 2016022630 A1 20160211 - ZHA JIPING [CN], et al
- [A] US 8420645 B2 20130416 - WENG LINGKAI [US], et al
- [Y] VISWANATH GUNDA ET AL: "Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, US, vol. 144, no. 9, 24 January 2019 (2019-01-24), pages 2266 - 2278, XP071290640, ISSN: 0020-7136, DOI: 10.1002/IJC.32041
- [Y] AHN HYUN KYUNG ET AL: "MET Receptor Tyrosine Kinase Regulates the Expression of Co-Stimulatory and Co-Inhibitory Molecules in Tumor Cells and Contributes to PD-L1-Mediated Suppression of Immune Cell Function", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 20, no. 17, 1 September 2019 (2019-09-01), Basel, CH, pages 4287, XP093176400, ISSN: 1422-0067, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6747314/pdf/ijms-20-04287.pdf> DOI: 10.3390/ijms20174287
- [Y] HONG DAVID ET AL: "A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors", ONCOLOGY : INTERNATIONAL JOURNAL OF CANCER RESEARCH AND TREATMENT, vol. 97, no. 2, 1 January 2019 (2019-01-01), CH, pages 102 - 111, XP093175143, ISSN: 0030-2414, Retrieved from the Internet <URL:https://karger.com/ocl/article-pdf/97/2/102/3296926/000500571.pdf> DOI: 10.1159/000500571
- [Y] GARCÍA-ARANDA MARILINA ET AL: "Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 20, no. 9, 9 May 2019 (2019-05-09), pages 2296, XP055864619, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6540309/pdf/ijms-20-02296.pdf> DOI: 10.3390/ijms20092296
- [AP] PUBCHEM: "Capmatinib | C23H17FN6O | CID 25145656 - PubChem", 19 June 2024 (2024-06-19), pages 1 - 28, XP093176548, Retrieved from the Internet <URL:https://pubchem.ncbi.nlm.nih.gov/compound/25145656>
- See also references of WO 2021244551A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

**EP 4159238 A1 20230405**; **EP 4159238 A4 20240807**; CN 115697407 A 20230203; US 2023263795 A1 20230824; WO 2021244551 A1 20211209

DOCDB simple family (application)

**EP 21817364 A 20210601**; CN 2021097776 W 20210601; CN 202180039048 A 20210601; US 202117999028 A 20210601